Find policies, billing codes, payers, states, and providers
CPT 87555: Mycobacterium tuberculosis Direct Nucleic Acid Probe Test
CPT code 87555 denotes a laboratory molecular assay that uses a direct nucleic acid probe to detect Mycobacterium tuberculosis. This diagnostic technique targets bacterial nucleic acid to rapidly identify tuberculosis infection in clinical specimens and plays a central role in timely diagnosis and infection control. Nationally, molecular diagnostics for tuberculosis remain important for public health surveillance, expedited treatment decisions, and laboratory workflow efficiency.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage and payment policies for molecular tuberculosis testing vary by payer and by clinical context, affecting site-of-service utilization between hospital and reference laboratories.
Readers will find an overview of clinical context for the assay, typical sites of service, common billing modifiers provided in the input, and an outline of what to expect in payer policy and reimbursement environments. The publication summarizes benchmarking and policy considerations relevant to laboratory managers, billing professionals, and clinicians engaged in tuberculosis diagnostics. Data not available in the input are noted where applicable.
Customize your policy alerts
Sign up for cpt 87555 policy alerts
Get alerted when payer policies referencing 87555 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 87555 describes a laboratory test that detects Mycobacterium tuberculosis using a direct nucleic acid probe technique. The procedure identifies genetic material specific to the bacterium, which is sometimes referred to as an acid-fast organism due to the specialized staining used in microscopy.
Service type: Laboratory diagnostic test — molecular assay (direct nucleic acid probe)
Typical site of service: Clinical laboratory or hospital laboratory